Alector prices $75 million equity offering of 36.6 million shares at $2.05
Alector, Inc. announced the pricing of an underwritten equity offering of 36.6 million common shares at $2.05 each, generating roughly $75 million in gross proceeds. Morgan Stanley and BTIG act as joint lead book‑running managers. The company said the net proceeds will support research and development, working capital and possible acquisitions, and the transaction is slated to close around October 19, 2026, subject to standard closing conditions.
Why it matters
The capital raise provides funding for Alector’s neurodegeneration pipeline and may enable strategic acquisitions, while diluting existing shareholders. The offering’s premium pricing and pre‑market price jump suggest market support for the financing.
Key facts
- 1Alector is selling 36,600,000 shares of common stock. stocktitan.net
- 2The offering price is $2.05 per share. tradingview.com
- 3Gross proceeds are expected to be about $75.03 million. tradingview.com
- 4Morgan Stanley & Co. LLC and BTIG, LLC are joint lead book‑running managers. stocktitan.net
- 5The transaction is anticipated to close around October 19, 2026, pending standard conditions. investing.com
- 6Proceeds will be used for research, development, working capital and potential acquisitions. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.